Juliet M Goodchild

Title: Juliet M Goodchild: Innovator in Neuroactive Steroids

Introduction

Juliet M Goodchild is a prominent inventor based in Melbourne, Australia. She has made significant contributions to the field of neuroprotection through her innovative research and patents. Her work focuses on the use of neuroactive steroids to address inflammation in the central nervous system.

Latest Patents

Juliet M Goodchild holds a patent titled "Neuroactive steroids and their use to facilitate neuroprotection." This patent outlines methods for treating inflammation or ameliorating neuroinflammatory-promoting conditions in the central nervous system. The invention emphasizes the use of non-hormonal neuroactive steroids, which are formulated in a sulfobutyl ether beta-cyclodextrin composition. The steroids mentioned in the patent include alphaxalone, alphadolone, allopregnanolone, pregnanolone, ganaxolone, hydroxydione, minaxolone, Org20599, Org21465, CT1341, and compounds of Formula (I). The patent also details the types of neuroinflammatory-promoting conditions, the specific cyclodextrin used, and the molar ratio of neuroactive steroid to cyclodextrin.

Career Highlights

Throughout her career, Juliet has been associated with several companies, including Goodchild Investments Pty Ltd and Drawbridge Pharmaceuticals Pty Ltd. Her work has been instrumental in advancing the understanding of neuroactive steroids and their therapeutic applications.

Collaborations

Juliet has collaborated with notable individuals in her field, including Colin S Goodchild and Colin Stanley Goodchild. These collaborations have contributed to her research and the development of her patented technologies.

Conclusion

Juliet M Goodchild is a trailblazer in the field of neuroactive steroids, with a focus on neuroprotection and inflammation treatment. Her innovative patent and career achievements highlight her significant impact on medical research and therapeutic advancements.